Trial Profile
Single-center, Open-label, Randomized, Two-way Crossover Study in Healthy Adult Male Subjects to Compare the Pharmacokinetics of Selexipag (ACT-293987) Following Single Oral Administration of 4 Film-coated Pediatric Tablets of 50 µg vs One Film-coated Tablet of 200 µg Selexipag
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Aug 2017
Price :
$35
*
At a glance
- Drugs Selexipag (Primary)
- Indications Arteriosclerosis obliterans; Pulmonary arterial hypertension; Pulmonary hypertension; Raynaud's disease
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 27 Jun 2017 Primary endpoint (Maximum plasma concentration (Cmax) of selexipag) has not been met as per the results presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics
- 27 Jun 2017 Primary endpoint (Maximum plasma concentration (Cmax) of ACT-333679) has been met as per the results presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics
- 27 Jun 2017 Primary endpoint (Area under plasma concentration-time curve [AUC(0-inf)] of selexipag and ACT-333679) has been met as per the results presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics